BioCentury | Oct 8, 2019

Novel targets induce cardiomyocyte regeneration

DISEASE CATEGORY: Cardiovascular INDICATION: Myocardial infarction (MI) Gene therapies delivering CCL24 or IGF2BP3 could restore cardiac function following MI. RNA-seq analysis identified 874 genes including CCL24 and IGF2BP3 that were upregulated in mouse heart tissue...
BioCentury | Oct 3, 2019
Targets & Mechanisms

Stimulating heart regeneration following injury

A multi-omic study of regenerating neonatal hearts has uncovered novel therapeutic targets for cardiac injury post myocardial infarction. Study leader Eric Olson said the findings serve as a resource for understanding the DNA sequences and...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...molecule CC chemokine receptor 3 (CCR3; CD193) inhibitor that blocks the action of chemokine CC motif ligand 11 (CCL11; eotaxin-1...
BioCentury | Dec 8, 2017
Financial News

OrbiMed , Thiel lead ChemomAb's $10M series B

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round on Dec. 4 led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The...
BioCentury | Dec 4, 2017
Financial News

OrbiMed, Thiel lead ChemomAb's $10M series B

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The company previously raised...
BioCentury | Nov 30, 2017
Clinical News

Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

...change in quality of life (QOL) score. Bertilimumab is a human mAb against chemokine CC motif ligand 11 (CCL11; eotaxin-1...
...Product: Bertilimumab (CAT-213, iCo-008) Business: Autoimmune Molecular target: Chemokine CC motif ligand 11 (CCL11; eotaxin-1) Description: Human mAb against eotaxin-1...
...change in quality of life (QOL) score Status: Phase II data Milestone: NA Claire Quang bertilimumab Immune Pharmaceuticals Inc. Chemokine CC motif ligand 11 (CCL11) (eotaxin-1)...
BioCentury | Mar 17, 2017
Clinical News

Bertilimumab: Preliminary Ph II data

...CAT-213) Business: Autoimmune Molecular target: Chemokine CC motif ligand 11 ( CCL11 ; eotaxin-1) Description: Human mAb against eotaxin-1...
...life (QOL) score Status: Preliminary Phase II data Milestone: NA Alicia Parker bertilimumab CAT-213 iCo-008 AstraZeneca plc iCo Therapeutics Inc. Immune Pharmaceuticals Inc. Chemokine CC motif ligand 11 (CCL11) (eotaxin-1)...
BioCentury | Sep 12, 2016
Emerging Company Profile

Age factors

...the same paper, Wyss-Coray and colleagues identified six plasma factors, including chemokine CC motif ligand 11 ( CCL11 ; eotaxin-1...
...so that they share a circulatory system. The researchers also showed that systemic administration of CCL11...
...degenerative factors in aged plasma, including CCL11 and B2M. The company is evaluating antibodies targeting CCL11...
BioCentury | Apr 4, 2016
Finance

Restructuring watch

...colitis data are expected in 4Q16. Immune Pharmaceuticals has rights to the human mAb against eotaxin-1...
BioCentury | Feb 8, 2016
Company News

iCo ophthalmic, autoimmune, infectious news

...AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.). iCo Therapeutics retains rights to the human mAb against eotaxin-1...
Items per page:
1 - 10 of 36